The circadian system maintains physiological homeostasis by precisely orchestrating 24-hour cycles of metabolic and cardiovascular functions. Circadian disruption has been substantiated as a contributor to cardiometabolic dysfunction, significantly elevating the risk of obesity, type 2 diabetes, hypertension, and cardiovascular diseases, thereby emerging as a crucial target for global chronic disease prevention. In 2025, the American Heart Association (AHA) issued a dedicated scientific statement that systematically reviewed the regulatory mechanisms of circadian rhythms and their intrinsic links to cardiometabolic health. It highlighted the pivotal role of modifiable behavioral factors, including light exposure, sleep-wake patterns, meal timing, and timing of physical activity, and proposed multi-faceted intervention strategies centered on chronotherapy. Considering the distinct circadian characteristics and chronic disease epidemiology in the Chinese population compared to Western counterparts, this article, grounded in the statement's core framework and incorporating evidence from localized Chinese research, provides a systematic interpretation of the biological basis of circadian rhythms, the pathophysiological mechanisms underlying disruption-related diseases, and potential intervention pathways. It particularly discusses the applicability of the statement's conclusions to clinical practice and public health strategies in China, aiming to offer an evidence-based reference for developing a cardiometabolic health support system tailored to the national context.
In May 2026, the American Heart Association (AHA) formally released the scientific statement "Secondary Prevention After Coronary Artery Bypass Graft Surgery: 2026 Update", which updates the 2015 statement. The new statement emphasizes a patient-centered shared decision-making model and further clarifies the application status of several novel drugs, including proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1a), and angiotensin receptor-neprilysin inhibitors (ARNIs), in coronary artery bypass grafting (CABG) patients with relevant indications. This article systematically summarizes and interprets the major recommendations of the statement. In conjunction with the current status of postoperative management after CABG in China, it discusses the potential applicability, implementation barriers, and future research directions of these recommendations, with the aim of providing practical guidance for cardiac surgeons and other clinicians involved in the long-term management of patients after CABG.